Successful desensitization to deferasirox in a paediatric patient with β‐Thalassaemia major

Davies, Grace Isobel; Davies, D. P.; Charles, Sarah; Barnes, Sara; Bowden, Donald Keith

doi:10.1111/pai.12677

Cited by 7 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those protocols took several days to achieve the target dose. There have been few reports on a n immediate hypersensitivity reaction (10)(11)(12)(13)(14). Therefore, we report a case of challengeproven immediate skin drug reaction in a TM patient with a long history of receiving deferoxamine (DFO) with no complications.…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Dermatopathological Drug Reaction in Thalassemia Major: A Case Report and a Brief Review

Shirkavand

Ataie‐Fashtami

Azarkeivan³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Thalassemia comprises a group of hereditary hemoglobinopathies. Thalassemia major presents with anemia within the first two years of life. These patients require frequent long-life blood transfusions for survival, leading to iron deposition in vital organs as related complications. The prognosis of Thalassemia major has improved because of the availability of iron‑chelating agents. Oral iron chelators are the mainstay of the chelation regimen. Deferasirox is a new‑generation oral iron chelator for daily usage. This case was novel for the severe, generalized dermatopathological drug reaction due to the generic form of deferasirox.Case presentation: This is a case presentation of adverse reaction in a TM patient who received oral deferasirox for the first time after years of Deferoxamine injection without any adverse reaction. There were generalized maculopapular, deep red- blue partly purpuric itchy skin rashes all over the body. The histopathological biopsy showed superficial perivascular or dermatitis with low-grade vasculopathy feature, few eosinophils, and mild psoriasiform-spoaglotic-lichenoid epidermal reaction more compatible with a clinical diagnosis of Drug ReactionConclusions: In the case of intrinsic characteristics, it is wiser and more cautious to initiate the original Deferasirox brand for the patients who are going to go under the oral chelating regimen and increase the daily dose more smoothly to cause patient Deferasirox through even three to four weeks for better tolerance.

show abstract

Section: Introductionmentioning

confidence: 96%

“…The common adverse effects of deferasirox are gastrointestinal events (15.2%), skin rash (10. 8%), and a transient increase in serum creatinine and elevations in liver enzyme levels (38%) (10)(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Dermatopathological Drug Reaction in Thalassemia Major: A Case Report and a Brief Review

Shirkavand

Ataie‐Fashtami

Azarkeivan³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…There were reports regarding successful DFX desensitization for delayed-type drug hypersensitivity reactions (DHR), including maculopapular eruption and erythema multiforme. 5 , 6 Those protocols took several days to achieve the target dose. There have been no reports on a challenge-proven immediate hypersensitivity reaction.…”

Section: Introductionmentioning

confidence: 99%

<p>Successful Deferasirox Rechallenge and Treating Through Reaction in a Patient with Challenge-Proven Mild Immediate Reaction: A Case Report</p>

Sompornrattanaphan

Krikeerati

Wongsa

et al. 2020

JAA

View full text Add to dashboard Cite

This is the first report of successful deferasirox administration, using graded challenge and treating through, in a patient with mild immediate hypersensitivity reaction. Beginning with drug graded challenges could indicate the eliciting dose and reaction severity which are important for the management plan in the next step. This approach could be a safe shortcut in a stable patient with a mild reaction and a long avoidance period.

show abstract

Deferasirox

2017

Reactions Weekly

View full text Add to dashboard Cite

Successful desensitization to deferasirox in a paediatric patient with β‐Thalassaemia major

Cited by 7 publications

References 14 publications

Dermatopathological Drug Reaction in Thalassemia Major: A Case Report and a Brief Review

Dermatopathological Drug Reaction in Thalassemia Major: A Case Report and a Brief Review

<p>Successful Deferasirox Rechallenge and Treating Through Reaction in a Patient with Challenge-Proven Mild Immediate Reaction: A Case Report</p>

Deferasirox

Contact Info

Product

Resources

About